Long-term gastrointestinal outcomes of COVID-19
2023/03/07 by Evan Xu, Yan Xie, Ziyad Al‐Aly · 1 voice · 141 citations
Medicine · Psychology · #Acute pancreatitis #COVID-19 Clinical Research Studies #COVID-19 and Mental Health #Cohort #Cohort study #Coronavirus disease 2019 (COVID-19) #Disease #GERD #Gastrointestinal bleeding #Infectious disease (medical specialty) #Intensive care medicine #Intensive care unit #Internal medicine #Long-Term Effects of COVID-19 #Medicine #Pandemic #Reflux
paper · pdf · doi:10.1038/s41467-023-36223-7
published in Nature Communications 14(1), 983 (Nature Portfolio)
openalex publication_date 2023/03/07 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/23
Abstract
A comprehensive evaluation of the risks and 1-year burdens of gastrointestinal disorders in the post-acute phase of COVID-19 is needed but is not yet available. Here we use the US Department of Veterans Affairs national health care databases to build a cohort of 154,068 people with COVID-19, 5,638,795 contemporary controls, and 5,859,621 historical controls to estimate the risks and 1-year burdens of a set of pre-specified incident gastrointestinal outcomes. We show that beyond the first 30 days of infection, people with COVID-19 exhibited increased risks and 1-year burdens of incident gastrointestinal disorders spanning several disease categories including motility disorders, acid related disorders (dyspepsia, gastroesophageal reflux disease, peptic ulcer disease), functional intestinal disorders, acute pancreatitis, hepatic and biliary disease. The risks were evident in people who were not hospitalized during the acute phase of COVID-19 and increased in a graded fashion across the severity spectrum of the acute phase of COVID-19 (non-hospitalized, hospitalized, and admitted to intensive care). The risks were consistent in comparisons including the COVID-19 vs the contemporary control group and COVID-19 vs the historical control group as the referent category. Altogether, our results show that people with SARS-CoV-2 infection are at increased risk of gastrointestinal disorders in the post-acute phase of COVID-19. Post-covid care should involve attention to gastrointestinal health and disease.
Citations
Cited by
- Long COVID science, research and policy
- New onset of severe and long-term hepatobiliary diseases post-COVID-19 infection: a systematic review
- Towards a cure for long COVID: the strengthening case for persistently replicating SARS‐CoV‐2 as a driver of post‐acute sequelae of COVID‐19
- Gastrointestinal Sequelae of COVID-19: Investigating Post-Infection Complications—A Systematic Review
- Overview and Pathophysiology of Long COVID
- A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
- Trends in Prevalence of Rome IV Disorders of Gut‐Brain Interaction During the COVID‐19 Pandemic: Results From a Nationally Representative Sample of Over 160,000 People in the US
- Mapping the effectiveness and risks of GLP-1 receptor agonists
- Progressive Increase in Small Intestinal Bacterial Overgrowth Risk Following COVID-19 Infection: A Global Population-Based Study
- Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study
- Adult Long Coronavirus Disease 2019
- Long-term Sequelae Following Dengue Infection vs SARS-CoV-2 Infection in a Pediatric Population: A Retrospective Cohort Study
- Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach
- T-cell repertoire response in individuals with post-acute sequelae of COVID-19
- Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. [europepmc]
- Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. [europepmc]
- Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. [europepmc]
- Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. [europepmc]
- ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. [europepmc]
- Microbiome and intestinal pathophysiology in post-acute sequelae of COVID-19. [europepmc]
- Postacute sequelae of COVID-19 at 2 years. [europepmc]
- Gut microbiota from patients with COVID-19 cause alterations in mice that resemble post-COVID symptoms. [europepmc]
- cGAS-STING signaling pathway in intestinal homeostasis and diseases. [europepmc]
- Dynamics of the Microbiota and Its Relationship with Post-COVID-19 Syndrome. [europepmc]
- Risks of digestive diseases in long COVID: evidence from a population-based cohort study. [europepmc]
- From Acute Infection to Prolonged Health Consequences: Understanding Health Disparities and Economic Implications in Long COVID Worldwide. [europepmc]
- Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID. [europepmc]
- Long COVID: Long-Term Impact of SARS-CoV2. [europepmc]
- Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. [europepmc]
- The Aftermath of COVID-19: Exploring the Long-Term Effects on Organ Systems. [europepmc]
- Microbial Signatures in COVID-19: Distinguishing Mild and Severe Disease via Gut Microbiota. [europepmc]
- Three-year outcomes of post-acute sequelae of COVID-19. [europepmc]
- Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death. [europepmc]
- Significance of Artificial Intelligence in the Study of Virus-Host Cell Interactions. [europepmc]
- Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK. [europepmc]
- Long COVID in Children and Adolescents: Mechanisms, Symptoms, and Long-Term Impact on Health-A Comprehensive Review. [europepmc]
- Pediatric Gastrointestinal Tract Outcomes During the Postacute Phase of COVID-19. [europepmc]
- A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. [europepmc]
- Prevalence of and factors associated with long COVID among US adults: a nationwide survey. [europepmc]
Discussions
Related